# Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

> **NCT03569293** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 912 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Placebo for Upadacitinib
- **DRUG:** Upadacitinib

## Key facts

- **NCT ID:** NCT03569293
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-13
- **Primary completion:** 2021-01-06
- **Final completion:** 2025-10-10
- **Target enrollment:** 912 (ACTUAL)
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03569293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03569293, "Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03569293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*